Sustained maintenance of exercise induced muscle strength gains and normal bone mineral density in patients with early rheumatoid arthritis: a 5 year follow up

A Häkkinen, T Sokka, H Kautiainen, A Kotaniemi, P Hannonen, A Häkkinen, T Sokka, H Kautiainen, A Kotaniemi, P Hannonen

Abstract

Objective: To investigate at 5 years whether an initial 2 year home based strength training period imposes sustained effects on muscle strength, bone mineral density (BMD), structural joint damage, and on disease activity in patients with early rheumatoid arthritis (RA).

Methods: Seventy patients were randomised either to perform home based strength training with loads of 50-70% of repetition maximum (EG) or range of motion exercises (CG). Both groups were encouraged to take part in aerobic activities 2-3 times a week. Maximal muscle strength of different muscle groups was measured by dynamometers, and BMD at the femoral neck and lumbar spine by dual x ray densitometry. Disease activity was assessed by the 28 joint disease activity score, and joint damage by x ray findings.

Results: 62 patients completed 2 years' training and 59 patients attended check up at 5 years. Mean (SD) maximum muscle strength indices increased from baseline to 2 years-in EG from 212 (78) kg by a mean (95% CI) of 68 (55 to 80) and in CG from 195 (72) kg by 35 (13 to 60) kg-and remained at that level for the next 3 years. Development of BMD in EG tended to be more favourable than that in CG. Muscle strength training was not detrimental to joint structures or disease activity.

Conclusion: The patients' exercise induced muscle strength gains during a 2 year training period were maintained throughout a subsequent self monitored training period of 3 years. Despite substantial training effects in muscle strength, BMD values remained relatively constant. Radiographic damage remained low even at 5 years.

Figures

Figure 1
Figure 1
Trial profile.
Figure 2
Figure 2
Disease modifying antirheumatic drugs taken by the experimental (A) and 31 control (B) patients with early RA. The percentage of patients taking each drug or combination over 5 years is shown. INFL, infliximab; COMBO+MTX, combination of DMARDs including methotrexate; DMARD, disease modifying antirheumatic drug; MTX, methotrexate; COMBO–MTX, combination of DMARDs without methotrexate; SSZ, sulfasalazine; MYO, intramuscular gold; HCQ, hydroxychloroquine.
Figure 3
Figure 3
Bone mineral density of the lumbar spine (A) and femoral neck (B) in the experimental (EG) and control groups (CG) at baseline and after 5 years' follow up.
Figure 4
Figure 4
Individual values of the Larsen scores in experimental (EG) and control (CG) groups at baseline and after 5 years' follow up.

References

    1. Clin Rheumatol. 1995 Jul;14(4):429-33
    1. Arthritis Rheum. 1980 Feb;23(2):137-45
    1. J Rheumatol. 1995 Oct;22(10):1974-5
    1. Arthritis Rheum. 1996 Mar;39(3):415-26
    1. Muscle Nerve. 1983 Feb;6(2):128-35
    1. Arthritis Rheum. 1987 Jul;30(7):721-8
    1. Arthritis Rheum. 1988 Mar;31(3):315-24
    1. Ann Rheum Dis. 1989 Jul;48(7):535-8
    1. Br J Rheumatol. 1991 Apr;30(2):86-90
    1. Ann Rheum Dis. 1992 Jan;51(1):35-40
    1. Ann Rheum Dis. 1993 Jan;52(1):21-6
    1. Clin Exp Rheumatol. 1993 Jul-Aug;11(4):381-5
    1. Phys Ther. 1994 Jan;74(1):32-9
    1. Ann Rheum Dis. 1994 Jan;53(1):18-23
    1. Arthritis Rheum. 1994 May;37(5):623-8
    1. Lancet. 1994 Jul 2;344(8914):23-7
    1. Eur J Appl Physiol Occup Physiol. 1994;68(4):322-6
    1. J Rheumatol. 1995 Jun;22(6):1055-9
    1. J Bone Miner Res. 1996 Apr;11(4):490-501
    1. Scand J Rheumatol. 1996;25(6):367-76
    1. Br J Rheumatol. 1997 Jan;36(1):43-9
    1. J Rheumatol. 1997 Jul;24(7):1285-7
    1. J Rheumatol. 1997 Aug;24(8):1531-9
    1. Physiother Res Int. 1999;4(1):55-67
    1. Ann Rheum Dis. 1999 Oct;58(10):618-22
    1. Arthritis Rheum. 2000 Mar;43(3):522-30
    1. J Rheumatol. 2000 Jul;27(7):1674-80
    1. Ann Rheum Dis. 2000 Aug;59(8):615-21
    1. Calcif Tissue Int. 2000 Jul;67(1):10-8
    1. Rheum Dis Clin North Am. 2000 Aug;26(3):617-46
    1. Am J Phys Med Rehabil. 2001 Jan;80(1):65-77
    1. Arthritis Rheum. 2001 Mar;44(3):515-22
    1. J Rheumatol. 2001 Apr;28(4):745-50
    1. Arthritis Rheum. 2001 Jun;44(6):1254-60
    1. Arthritis Rheum. 2001 Dec;44(12):2707-10
    1. Arthritis Rheum. 2001 Dec;44(12):2737-45
    1. Arthritis Rheum. 2002 Feb;46(2):347-56
    1. Ann Rheum Dis. 2002 Apr;61(4):325-9
    1. Rheumatology (Oxford). 2002 Sep;41(9):1047-51
    1. Scand J Med Sci Sports. 2003 Feb;13(1):3-8
    1. Arthritis Rheum. 2003 Apr 15;49(2):263-6
    1. Acta Radiol Diagn (Stockh). 1977 Jul;18(4):481-91
    1. Scand J Rheumatol. 1977;6(3):189-92
    1. J Bone Miner Res. 1995 Jul;10(7):1015-24

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever